prk, a Cytokine-inducible Human Protein Serine/Threonine Kinase Whose Expression Appears to be Down-regulated in Lung Carcinomas*
- Bo Li‡,
- Bin Ouyang‡,
- Huiqi Pan‡,
- Peter T. Reissmann‡,
- Dennis J. Slamon§,
- Robert Arceci¶,
- Luo Lu∥ and
- Wei Dai”
- From the ‡ Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267,
- the § Department of Medicine, UCLA, Los Angeles, California 90095,
- the ¶ Children's Hospital Research Foundation, Cincinnati, Ohio 45229, and
- the ∥ Department of Physiology and Biophysics, Wright State University, Dayton, Ohio 45435
- ” To whom correspondence should be addressed: Division of Hematology and Oncology, Dept. of Internal Medicine, University of Cincinnati College of Medicine, ML-508, K-Pavilion, 231 Bethesda Ave., Cincinnati, OH 45267. Tel.: 513-558-4445; Fax: 513-558-6703.
Abstract
We have cloned and characterized a putative protein serine/threonine kinase termed prk through a combination of polymerase chain reaction and conventional cDNA library screening approaches. There are apparently two distinct domains within prk protein deduced from its nucleotide sequences. The amino-terminal portion has the feature of the catalytic domain of a serine/threonine kinase and shows strong homology to mouse fnk and other polo family kinases including mouse snk, human and murine plk, Drosophila polo, and yeast Cdc5. The carboxyl-terminal portion, presumably the regulatory domain, shares extensive homology to mouse fnk. Northern blotting analyses reveal that prk expression is restricted to a very limited number of tissues with placenta, ovaries, and lung containing detectable amounts of prk mRNA. prk mRNA expression is also detected at a low level in the megakaryocytic cell line Dami, MO7e, and three brain glioma cell lines. In addition, refeeding of serum-deprived MO7e, Dami, and K562 cells of hematopoietic origin and GMOO637D of lung fibroblasts rapidly activates prk mRNA expression with its peak induction around 2 h after serum addition. prk gene activation by the serum requires no new protein synthesis. The recombinant cytokines such as interleukin-3 and thrombopoietin also activate prk mRNA expression in MO7e cells. Furthermore, a survey of RNAs isolated from the tumor and the uninvolved tissues from 18 lung cancer patients reveals that prk mRNA expression is significantly down-regulated in tumor tissues. Southern blotting analysis indicates that the prk gene is present in a single copy in the genome of tumors and normal cells. Taken together, these results suggest that prk expression may be restricted to proliferating cells and involved in the regulation of cell cycle progression. The molecular cloning of prk cDNA will facilitate the study of its biological role as well as its potential role in tumorigenesis.
Footnotes
-
↵* This work was supported in part by United States Public Health Service Award RO1CA59985. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EMBL Data Bank with accession number(s) U56998[GenBank].
-
↵1 The abbreviations used are:
- PCR
-
polymerase chain reaction
- RACE
-
rapid amplification of cDNA end
- IL-3
-
interleukin-3
- TGF-β
-
transforming growth factor-β
- FBS
-
fetal bovine serum.
-
- Received February 15, 1996.
- Revision received May 24, 1996.
- © 1996 by The American Society for Biochemistry and Molecular Biology, Inc.











